Cantitate/Preț
Produs
Total produse
Vezi coșul
Resistance to Molecular Therapies for Hepatocellular Carcinoma de Augusto Villanueva

Resistance to Molecular Therapies for Hepatocellular Carcinoma: Resistance to Targeted Anti-Cancer Therapeutics, cartea 13

Editat de Augusto Villanueva
en Limba Engleză Hardback – 27 iul 2017
This volume evaluates the clinical patterns of resistance to sorafenib, the impact of trial design in the second-line setting and the current gold standard to define radiological resistance; describes the molecular mechanisms responsible for treatment resistance in HCC patients, including components of the immune system and tumor microenvironment; determines the role of the cancer stem cell phenotype in resistance; reviews the experimental models to study resistance; and addresses new approaches to overcome resistance to sorafenib, using successful examples from other malignancies. 
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 96607 lei  38-44 zile
  Springer International Publishing – 2 aug 2018 96607 lei  38-44 zile
Hardback (1) 107171 lei  6-8 săpt.
  Springer International Publishing – 27 iul 2017 107171 lei  6-8 săpt.

Din seria Resistance to Targeted Anti-Cancer Therapeutics

  • 5% Current Applications for Overcoming Resistance to Targeted Therapies
    Preț: 70357 lei
  • 5% Resistance to Proteasome Inhibitors in Cancer: Molecular Mechanisms and Strategies to Overcome Resistance
    Preț: 108479 lei
  • 5% Resistance to Tyrosine Kinase Inhibitors
    Preț: 107388 lei
  • 5% Resistance to Targeted Therapies Against Adult Brain Cancers
    Preț: 107799 lei
  • 5% Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy: Targeted Therapies to Reverse Resistance
    Preț: 107120 lei
  • 5% TRAIL, Fas Ligand, TNF and TLR3 in Cancer
    Preț: 108088 lei
  • 5% Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways
    Preț: 107708 lei
  • 5% Resistance to Targeted Therapies in Breast Cancer
    Preț: 107388 lei
  • 5% Resistance of Targeted Therapies Excluding Antibodies for Lymphomas
    Preț: 82400 lei
  • 5% Resistance to Ibritumomab in Lymphoma
    Preț: 70144 lei
  • 5% Cancer Stem Cell Resistance to Targeted Therapy
    Preț: 70037 lei
  • 5% Resistance to Immunotherapeutic Antibodies in Cancer: Strategies to Overcome Resistance
    Preț: 107171 lei
  • 5% Resistance to Targeted Therapies in Lymphomas
    Preț: 69785 lei
  • 5% Resistance to Targeted Therapies in Multiple Myeloma
    Preț: 100382 lei
  • 5% Resistance to Targeted ABC Transporters in Cancer
    Preț: 70894 lei
  • 5% Resistance to Photodynamic Therapy in Cancer
    Preț: 70662 lei
  • 5% Resistance to Immunotoxins in Cancer Therapy
    Preț: 70662 lei
  • 5% Resistance of Cancer Cells to CTL-Mediated Immunotherapy
    Preț: 71198 lei
  • 5% Resistance to Aromatase Inhibitors in Breast Cancer
    Preț: 70859 lei
  • 5% Defects in T Cell Trafficking and Resistance to Cancer Immunotherapy
    Preț: 70322 lei

Preț: 107171 lei

Preț vechi: 112812 lei
-5% Nou

Puncte Express: 1608
Preț estimativ în valută:
20510€ • 21305$ • 17037£

Carte tipărită la comandă

Livrare economică 03-17 februarie 25

 Adaugă în coș

Wish list
Gift list
Am citit!
Adaugă în listă
Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783319561967
ISBN-10: 3319561960
Pagini: 142
Ilustrații: XIII, 147 p. 16 illus. in color.
Dimensiuni: 155 x 235 mm
Greutate: 0.41 kg
Ediția:1st ed. 2017
Editura: Springer International Publishing
Colecția Springer
Seria Resistance to Targeted Anti-Cancer Therapeutics

Locul publicării:Cham, Switzerland

Cuprins

Tumor Heterogeneity and Resistance to Targeted Therapies in Hepatocellular Carcinoma.- Modulating Immune Responses to Overcome Resistance in Hepatocellular Carcinoma.- Role of Tumor Microenvironment in Hepatocellular Carcinoma Resistance.- Contribution of the Cancer Stem Cell Phenotype to Hepatocellular Carcinoma Resistance.- Clinical and Preclinical Perspectives on Mechanisms  of Sorafenib Resistance in Hepatocellular Carcinoma.- Radiological Assessment of Response to Palliative Treatments in Hepatocellular Carcinoma.- Sorafenib and Clinical Patterns of Resistance in hepatocellular carcinoma.- Overcoming Treatment Resistance in Hepatocellular Carcinoma: regorafenib and lessons from other malignancies.

Notă biografică

Augusto Villanueva, MD, PhD, is Assistant Professor, Division of Liver Diseases, Liver Cancer Program, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine, NYC.

Textul de pe ultima copertă

This volume evaluates the clinical patterns of resistance to sorafenib, the impact of trial design in the second-line setting and the current gold standard to define radiological resistance; describes the molecular mechanisms responsible for treatment resistance in HCC patients, including components of the immune system and tumor microenvironment; determines the role of the cancer stem cell phenotype in resistance; reviews the experimental models to study resistance; and addresses new approaches to overcome resistance to sorafenib, using successful examples from other malignancies.

Caracteristici

This book will evaluate the clinical patterns of resistance to sorafenib, the impact of trial design in the second-line setting and the current gold-standard to define radiological resistance This book will describe the molecular mechanisms responsible for treatment resistance in HCC patients, including components of the immune system and tumor microenvironment This book will help determine the role of the cancer stem cell phenotype in resistance This book will review the experimental models to study resistance This book will address new approaches to overcome resistance to sorafenib, using successful examples from other malignancies